Collaborative Arrangements (Tables)

6 Months Ended

Jun. 30, 2020

Collaborative Arrangements [Abstract]

Collaboration Arrangements

Summarized financial information related to this collaboration is as follows:

	Three Months Ended   June 30,				Six Months Ended   June 30,
($ in millions)	2020		2019		2020		2019
Alliance revenue - Lynparza	$	178	$	111	$	323	$	190
Cost of sales (1)	137		73		164		92
Selling, general and administrative	39		33		72		59
Research and development	37		33		73		78
($ in millions)					June 30, 2020		December 31, 2019
Receivables from AstraZeneca included in Other current assets					$	168	$	128
Payables to AstraZeneca included in Accrued and other current liabilities (2)					324		577
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)					400		—

⁽¹⁾ Represents amortization of capitalized milestone payments.

⁽²⁾ Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:

	Three Months Ended   June 30,				Six Months Ended   June 30,
($ in millions)	2020		2019		2020		2019
Alliance revenue - Adempas	$	79	$	51	$	133	$	94
Net sales of Adempas recorded by Merck	57		53		113		100
Total sales	$	136	$	104	$	246	$	194
Cost of sales (1)	28		29		57		58
Selling, general and administrative	17		11		28		20
Research and development	16		32		41		62
($ in millions)					June 30, 2020		December 31, 2019
Receivables from Bayer included in Other current assets					$	62	$	49
Payables to Bayer included in Other Noncurrent Liabilities (2)					375		375

⁽¹⁾ Includes amortization of intangible assets.

⁽²⁾ Represents accrued milestone payment.

Summarized financial information related to this collaboration is as follows:

	Three Months Ended   June 30,				Six Months Ended   June 30,
($ in millions)	2020		2019		2020		2019
Alliance revenue - Lenvima	$	151	$	97	$	279	$	171
Cost of sales (1)	135		23		170		74
Selling, general and administrative	19		19		31		38
Research and development	56		62		120		109
($ in millions)					June 30, 2020		December 31, 2019
Receivables from Eisai included in Other current assets					$	173	$	150
Payables to Eisai included in Accrued and other current liabilities (2)					325		700
Payables to Eisai included in Other Noncurrent Liabilities (3)					570		525

⁽¹⁾ Represents amortization of capitalized milestone payments.

⁽²⁾ Includes accrued milestone and future option payments.

⁽³⁾ Includes accrued milestone payments.